Homozygous Inversion on Chromosome 13 Involving SGCG Detected by Short Read Whole Genome Sequencing in a Patient Suffering from Limb-Girdle Muscular Dystrophy

Genes (Basel). 2022 Sep 28;13(10):1752. doi: 10.3390/genes13101752.

Abstract

New techniques in molecular genetic diagnostics now allow for accurate diagnosis in a large proportion of patients with muscular diseases. Nevertheless, many patients remain unsolved, although the clinical history and/or the muscle biopsy give a clear indication of the involved genes. In many cases, there is a strong suspicion that the cause must lie in unexplored gene areas, such as deep-intronic or other non-coding regions. In order to find these changes, next-generation sequencing (NGS) methods are constantly evolving, making it possible to sequence entire genomes to reveal these previously uninvestigated regions. Here, we present a young woman who was strongly suspected of having a so far genetically unsolved sarcoglycanopathy based on her clinical history and muscle biopsy. Using short read whole genome sequencing (WGS), a homozygous inversion on chromosome 13 involving SGCG and LINC00621 was detected. The breakpoint in intron 2 of SGCG led to the absence of γ-sarcoglycan, resulting in the manifestation of autosomal recessive limb-girdle muscular dystrophy 5 (LGMDR5) in the young woman.

Keywords: LGMDR5; SGCG; genetic diagnostics; inversion; muscle disease; next generation sequencing (NGS); sarcoglycanopathy; whole genome sequencing (WGS).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromosomes, Human, Pair 13
  • Female
  • Homozygote
  • Humans
  • Muscular Dystrophies, Limb-Girdle* / diagnosis
  • Muscular Dystrophies, Limb-Girdle* / genetics
  • Sarcoglycans* / genetics
  • Whole Genome Sequencing

Substances

  • Sarcoglycans
  • SGCG protein, human

Grants and funding

This research was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—444748124.